四环生物(000518) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥50,357,114.91, a decrease of 28.96% compared to ¥70,884,919.88 in the same period last year[3] - The net profit attributable to shareholders was -¥23,275,808.58, representing a decline of 75.43% from -¥13,267,948.59 year-on-year[3] - The net loss for the current period was CNY 25,909,848.63, compared to a net loss of CNY 14,969,513.54 in the previous period[16] - The total comprehensive income for the period was -25,909,848.63 CNY, compared to -14,969,513.54 CNY in the previous year[20] - Basic and diluted earnings per share were both -0.0226 CNY, worsening from -0.0129 CNY in the same quarter last year[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 55.79%, amounting to -¥7,374,282.57 compared to -¥16,678,791.31 in the previous year[3] - Cash and cash equivalents at the end of the period were 28,308,162.95 CNY, down from 35,891,192.89 CNY at the end of the previous year[21] - The company did not report any cash inflow from investment activities, resulting in a net cash flow from investing activities of -1,779,000.00 CNY[21] - The net cash flow from financing activities was -387,375.01 CNY, compared to -188,250.01 CNY in the previous year[21] Assets and Liabilities - Total assets decreased by 7.17% to ¥741,995,891.33 from ¥799,312,074.12 at the end of the previous year[3] - Total liabilities decreased to CNY 121,129,369.35 from CNY 152,535,703.51, a decrease of approximately 20.6%[13] - The company's total equity decreased to CNY 620,866,521.98 from CNY 646,776,370.61, a decline of about 4.0%[13] Research and Development - The company's R&D expenses were ¥13,931,832.09, down 32.63% from ¥20,679,688.39 in the same period last year, indicating a slowdown in R&D progress[6] - Research and development expenses were CNY 13,931,832.09, down from CNY 20,679,688.39, a decrease of approximately 32.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 116,524[8] - The top shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares[8] Credit and Impairment - The company reported a significant increase in credit impairment losses, with a rise of 2319.16% to -¥5,636,224.03 due to adjustments in expected credit loss rates[6] Product Development and Market Strategy - The company did not report any new product developments or market expansion strategies during this quarter[10] - There were no new product launches or significant technological advancements reported during the quarter[20] Audit Status - The report was not audited, indicating that the figures may be subject to change upon further review[22]